562 related articles for article (PubMed ID: 33105713)
21. LncRNA PlncRNA-1 accelerates the progression of prostate cancer by regulating PTEN/Akt axis.
Cui Z; Gao H; Yan N; Dai Y; Wang H; Wang M; Wang J; Zhang D; Sun P; Qi T; Wang Q; Kang W; Jin X
Aging (Albany NY); 2021 Apr; 13(8):12113-12128. PubMed ID: 33848262
[TBL] [Abstract][Full Text] [Related]
22. PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling.
Conley-LaComb MK; Saliganan A; Kandagatla P; Chen YQ; Cher ML; Chinni SR
Mol Cancer; 2013 Jul; 12(1):85. PubMed ID: 23902739
[TBL] [Abstract][Full Text] [Related]
23. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.
Cloughesy TF; Yoshimoto K; Nghiemphu P; Brown K; Dang J; Zhu S; Hsueh T; Chen Y; Wang W; Youngkin D; Liau L; Martin N; Becker D; Bergsneider M; Lai A; Green R; Oglesby T; Koleto M; Trent J; Horvath S; Mischel PS; Mellinghoff IK; Sawyers CL
PLoS Med; 2008 Jan; 5(1):e8. PubMed ID: 18215105
[TBL] [Abstract][Full Text] [Related]
24. Identification of the PTEN-ARID4B-PI3K pathway reveals the dependency on ARID4B by PTEN-deficient prostate cancer.
Wu RC; Young IC; Chen YF; Chuang ST; Toubaji A; Wu MY
Nat Commun; 2019 Sep; 10(1):4332. PubMed ID: 31551414
[TBL] [Abstract][Full Text] [Related]
25. Proproliferative function of adaptor protein GRB10 in prostate carcinoma.
Khan MI; Al Johani A; Hamid A; Ateeq B; Manzar N; Adhami VM; Lall RK; Rath S; Sechi M; Siddiqui IA; Choudhry H; Zamzami MA; Havighurst TC; Huang W; Ntambi JM; Mukhtar H
FASEB J; 2019 Mar; 33(3):3198-3211. PubMed ID: 30379590
[TBL] [Abstract][Full Text] [Related]
26. Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition.
González-Billalabeitia E; Seitzer N; Song SJ; Song MS; Patnaik A; Liu XS; Epping MT; Papa A; Hobbs RM; Chen M; Lunardi A; Ng C; Webster KA; Signoretti S; Loda M; Asara JM; Nardella C; Clohessy JG; Cantley LC; Pandolfi PP
Cancer Discov; 2014 Aug; 4(8):896-904. PubMed ID: 24866151
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer.
Yamamoto Y; De Velasco MA; Kura Y; Nozawa M; Hatanaka Y; Oki T; Ozeki T; Shimizu N; Minami T; Yoshimura K; Yoshikawa K; Nishio K; Uemura H
J Transl Med; 2015 May; 13():150. PubMed ID: 25953027
[TBL] [Abstract][Full Text] [Related]
28. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.
Martin AM; Nirschl TR; Nirschl CJ; Francica BJ; Kochel CM; van Bokhoven A; Meeker AK; Lucia MS; Anders RA; DeMarzo AM; Drake CG
Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):325-32. PubMed ID: 26260996
[TBL] [Abstract][Full Text] [Related]
29. The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.
Mendes RD; Canté-Barrett K; Pieters R; Meijerink JP
Haematologica; 2016 Sep; 101(9):1010-7. PubMed ID: 27582570
[TBL] [Abstract][Full Text] [Related]
30. Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression.
Patel R; Gao M; Ahmad I; Fleming J; Singh LB; Rai TS; McKie AB; Seywright M; Barnetson RJ; Edwards J; Sansom OJ; Leung HY
J Clin Invest; 2013 Mar; 123(3):1157-75. PubMed ID: 23434594
[TBL] [Abstract][Full Text] [Related]
31. PTEN loss correlates with T cell exclusion across human cancers.
Lin Z; Huang L; Li SL; Gu J; Cui X; Zhou Y
BMC Cancer; 2021 Apr; 21(1):429. PubMed ID: 33874915
[TBL] [Abstract][Full Text] [Related]
32. Dp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells.
Dixon KM; Lui GY; Kovacevic Z; Zhang D; Yao M; Chen Z; Dong Q; Assinder SJ; Richardson DR
Br J Cancer; 2013 Feb; 108(2):409-19. PubMed ID: 23287991
[TBL] [Abstract][Full Text] [Related]
33. NVP-BEZ235, a dual PI3K/mTOR inhibitor, induces cell death through alternate routes in prostate cancer cells depending on the PTEN genotype.
Hong SW; Shin JS; Moon JH; Kim YS; Lee J; Choi EK; Ha SH; Lee DH; Chung HN; Kim JE; Kim KP; Hong YS; Lee JL; Lee WJ; Choi EK; Lee JS; Jin DH; Kim TW
Apoptosis; 2014 May; 19(5):895-904. PubMed ID: 24652480
[TBL] [Abstract][Full Text] [Related]
34. Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathways.
Xing C; Ci X; Sun X; Fu X; Zhang Z; Dong EN; Hao ZZ; Dong JT
Neoplasia; 2014 Nov; 16(11):883-99. PubMed ID: 25425963
[TBL] [Abstract][Full Text] [Related]
35. PTEN: What we know of the function and regulation of this onco-suppressor factor in bladder cancer?
Ashrafizadeh M; Zarrabi A; Samarghandian S; Najafi M
Eur J Pharmacol; 2020 Aug; 881():173226. PubMed ID: 32485246
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of the phosphatidylinositol 3'-kinase pathway promotes autocrine Fas-induced death of phosphatase and tensin homologue-deficient prostate cancer cells.
Bertram J; Peacock JW; Tan C; Mui AL; Chung SW; Gleave ME; Dedhar S; Cox ME; Ong CJ
Cancer Res; 2006 May; 66(9):4781-8. PubMed ID: 16651432
[TBL] [Abstract][Full Text] [Related]
37. PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy.
Fraser M; Zhao H; Luoto KR; Lundin C; Coackley C; Chan N; Joshua AM; Bismar TA; Evans A; Helleday T; Bristow RG
Clin Cancer Res; 2012 Feb; 18(4):1015-27. PubMed ID: 22114138
[TBL] [Abstract][Full Text] [Related]
38. Preferential chemosensitization of PTEN-mutated prostate cells by silencing the Akt kinase.
Priulla M; Calastretti A; Bruno P; Azzariti A; Paradiso A; Canti G; Nicolin A
Prostate; 2007 May; 67(7):782-9. PubMed ID: 17373720
[TBL] [Abstract][Full Text] [Related]
39. AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis.
Li N; Xue W; Yuan H; Dong B; Ding Y; Liu Y; Jiang M; Kan S; Sun T; Ren J; Pan Q; Li X; Zhang P; Hu G; Wang Y; Wang X; Li Q; Qin J
J Clin Invest; 2017 Apr; 127(4):1284-1302. PubMed ID: 28319045
[TBL] [Abstract][Full Text] [Related]
40. Knockdown of Phospholipase Cε (PLCε) Inhibits Cell Proliferation via Phosphatase and Tensin Homolog Deleted on Chromosome 10 (PTEN)/AKT Signaling Pathway in Human Prostate Cancer.
Wang X; Fan Y; Du Z; Fan J; Hao Y; Wang J; Wu X; Luo C
Med Sci Monit; 2018 Jan; 24():254-263. PubMed ID: 29330357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
